White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
CAMBRIDGE, Mass., April 27, 2017 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, May 4, 2017 at 9:00 a.m. ET to discuss financial results for the first quarter 2017. Genocea management will also provide an update on the Company's recent progress and upcoming milestones.
Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and refer to conference ID number 13446635. To join the live webcast, please visit the investor relations section of the Genocea website at http://ir.genocea.com.
A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.
About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea used ATLAS to identify the antigens in its lead clinical candidate, GEN-003, an investigational immunotherapy to treat genital herpes, and is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines and to identify T cell response signatures of cancer patients treated with checkpoint blockade therapies to potentially improve clinical practice. Genocea expects GEN-003 to be ready to begin Phase 3 development and to file an IND for its neoantigen cancer vaccine candidate GEN-009 by the end of 2017. For more information, please visit the company's website at www.genocea.com.
For media: Jennifer LaVin O: 617-715-6687 [email protected] For investors: Jonathan Poole O: 617-876-8191 [email protected]
